Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

LAMA2-TFIMG

Financiado

Tackling fibrosis and inflammation in LAMA2-RD by in vivo modulation of a novel...

Tackling fibrosis and inflammation in LAMA2-RD by in vivo modulation of a novel modifier gene Merosin-deficient congenital muscular dystrophy (LAMA2-RD) is caused by mutations in the LAMA2 gene, coding for the α2 subunit of laminin-211 (merosin). Typically, LAMA2-RD patients with absent merosin are clinically severe and un... ver más

31/12/2026

OSR

173K€

Presupuesto del proyecto: 173K€

Líder del proyecto

OSPEDALE SAN RAFFAELE SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-04-24

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

OSR

172.75K€ | Lider

Proyectos interesantes

PID2021-125978OB-C22 COMPRENSION DE LA ATROFIA MUSCULAR INDUCIDA POR TNPO3 MUTANT... 242K€ Cerrado

SAF2015-64500-R MODULACION TERAPEUTICA DE LA EXPRESION DE GENES PATOGENICOS... 175K€ Cerrado

RTI2018-094599-B-I00 COMPRENSION DE LAS CAUSAS MOLECULARES DE LA ATROFIA MUSCULAR... 224K€ Cerrado

PID2020-117058GB-I00 EL PAPEL DE LOS FACTORES DE REGULACION MIOGENICA SOBRE LA DI... 206K€ Cerrado

SAF2012-36854 UTILIZACION DE MICRORNAS COMO DIANAS TERAPEUTICAS Y BIOMARCA... 176K€ Cerrado

MyoPALM Deciphering the role of protein S-palmitoylation in skeletal... 321K€ Cerrado

Últimas noticias

02-12-2024: AGENCIA-VALENCIANA-D... En las últimas 48 horas el Organismo AGENCIA VALENCIANA D... ha otorgado 1 concesiones

02-12-2024: CDTI En las últimas 48 horas el Organismo CDTI ha otorgado 4 concesiones

01-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 1337 concesiones

Duración del proyecto: 32 meses Fecha Inicio: 2024-04-24
Fecha Fin: 2026-12-31

Líder del proyecto

OSPEDALE SAN RAFFAELE SRL

TRL 4-5

Presupuesto del proyecto 173K€

Descripción del proyecto Merosin-deficient congenital muscular dystrophy (LAMA2-RD) is caused by mutations in the LAMA2 gene, coding for the α2 subunit of laminin-211 (merosin). Typically, LAMA2-RD patients with absent merosin are clinically severe and unable to walk, while those producing a partially functional merosin are clinically milder. I identified a unique family in which the oldest of two affected siblings shows a novel and extremely mild phenotype despite the complete lack of merosin. This patient is still ambulant at 33 years with no respiratory insufficiency or cardiomyopathy. Notably, this patient carries the same LAMA2 loss-of-function mutation as the sibling who followed the typical severe disease course. Hypothesizing that genetic modifier(s) in the atypical patient mitigate the consequences of complete merosin deficiency via a novel mechanism, I isolated unique ultra-rare polymorphisms in genetic factors related to genes expressed in the atypical patient muscle but not in muscle of non-related LAMA2-RD patients, and I identified a novel candidate modifier controlling both fibrosis and inflammation (key drivers of LAMA2-RD pathogenesis). Given that this modifier is severely upregulated in the control LAMA2-RD patients but highly downregulated in the atypical patient, I will decrease its expression in the severely affected LAMA2-RD mouse model DyW/DyW by using the CRISPR-interference tool delivered by a single AAV9. I will then assess motor strength and endurance in treated mice. Finally, I will isolate highly affected muscles and sciatic nerve to characterize any molecular and morphological change occurring in these tissues upon modulating the modifier gene expression. I expect to observe functional improvement in LAMA2-RD animals, thus ameliorating their phenotype. The proposed project will elucidate novel mechanisms attenuating LAMA2-RD severity and will allow me to design new therapeutic approaches for this disorder for which, to date, there is no approved treatment.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores